<DOC>
	<DOCNO>NCT02777658</DOCNO>
	<brief_summary>The objective study assess molecular testing , treatment pattern , associate outcome among patient EGFR ( Epidermal Growth Factor Receptor ) mutation-positive locally advanced advanced NSCLC ( Non-Small Cell Lung Cancer ) progress EGFR-TKI ( EGFR-Tyrosine Kinase Inhibitor ) therapy post availability third-generation TKI ( primary study cohort ) . Additionally , molecular test treatment pattern assess among secondary cohort patient include patient diagnose de-novo EGFR T790M mutation-positive locally advanced advanced NSCLC .</brief_summary>
	<brief_title>PANORAMA - Real World Molecular Testing , Treatment Patterns , Clinical Outcomes EGFR Mutation-Positive NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Inclusion Criteria Primary Study Cohort Provision write informed consent ( patient consent within 6 week disease progression , define elsewhere Index Date ) Adult male female subject ( accord age majority/adulthood define local regulation ) Patients prior confirm EGFR mutationpositive ( mutation ) locally advance advanced NSCLC Patients develop resistance EGFRTKI due phenotypic/histologic transformation ( e.g. , smallcell lung cancer , EMT ) mutation ( e.g. , HER2 , MET amplification ) indexdate eligible participation study long prior confirm diagnosis EGFR mutationpositive ( mutation ) locally advance advanced NSCLC Patients progress EGFRTKI therapy ( i.e. , gefitinib , erlotinib afatinib ) within patient selection period Inclusion Criteria Secondary Study Cohort Provision write informed consent ( patient consent within 6 week NSCLC diagnosis , define elsewhere Index Date ) Adult male female subject ( accord age majority/adulthood define local regulation ) Patients diagnose denovo EGFR T790M mutationpositive locally advance advanced NSCLC patient selection period . The denovo T790M mutation alone combination mutation ( e.g. , L858R T790M ) . Exclusion Criteria Primary Secondary Study Cohorts â€¢ Enrollment study prohibit participation noninterventional study . These patient censor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Epidermal Growth Factor Receptor ( EGFR ) , non-small cell lung cancer ( NSCLC ) , EGFR T790M , EGFR Mutation-Positive Locally Advanced Advanced NSCLC</keyword>
</DOC>